Title: Sarcopenia in acute care patients: Protocol for the European Collaboration of Geriatric Surveys: Sarcopenia EAMA9+ project

Keywords: Acute sarcopenia; hospitalized older patients; FRAIL; Global Leadership Initiative on Malnutrition criteria; European collaboration; European Academy for Medicine of Ageing

Corresponding Author: Dr. Dolores Sánchez-Rodríguez, MD PhD


First Author: Dolores Sánchez-Rodríguez, MD PhD

Order of Authors: Dolores Sánchez-Rodríguez, MD PhD; Suzy Hope, MB ChB PhD; Karolina Piotrowicz, MD PhD; Florence Benoit, MD; A Czesak, MD PhD; Dhayana Dallmeier, MD PhD; Genia Decker; Anette Hansen Hojmann, MD PhD; Dana Hrnčiarikova, MD PhD; Ester Marco, MD PhD; Delky Meza, MD; Murielle Surquin, MD PhD; Miguel Toscano-Rico, MD PhD; Hana Vankova, MD PhD; Davide L Vetrano, MD PhD; Jerzy Gasowski, MD PhD; Nele Van Den Noortgate, MD PhD; Francesco Landi, MD PhD
Letter to the editor

Sarcopenia in acute care patients: Protocol for the European Collaboration of Geriatric Surveys: Sarcopenia 9+ EAMA project

Dolores Sanchez-Rodriguez* MD PhD1-5; Suzy Hope* MBChB PhD6,7; Karolina Piotrowicz* MD PhD8,9; Florence Benoit MD10; A Czesak MD PhD8,9; Dhayana Dallmeier MD PhD11,12; Genia Decker11-12; Anette Hansen Højmann MD PhD13; Dana Hrnciarikova MD PhD14; Ester Marco MD PhD2,3,15,16; Delky Meza MD2,4; Murielle Surquin MD PhD10; Miguel Toscano-Rico MD17,18; Hana Vankova MD PhD14; Davide L. Vetrano19,20; Jerzy Gąsowski MD, PhD8; Nele Van Den Noortgate MD PhD21; Francesco Landi MD PhD20

1. Geriatrics Department. Parc Salut Mar, Barcelona, Spain
2. Rehabilitation Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
3. School of Medicine, Universitat Autònoma de Barcelona, Spain
4. Department of Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
5. WHO Collaborating Center for Public Health Aspects of Muscle-Skeletal Health and Ageing. Research Unit in Public Health, Epidemiology and Health Economics. Department of Public Health, Epidemiology and Health Economics, University of Liège. CHU - Sart Tilman, Liège, Belgium.
6. University of Exeter Medical School, Exeter, United Kingdom
7. Healthcare for Older People Department, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK
8. Faculty of Medicine. Department of Internal Medicine and Gerontology, Jagiellonian University, Krakow, Poland
9. University Hospital, Krakow, Poland
10. Geriatrics Department. CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
11. Geriatric Center Ulm/Alb-Donau, Ulm University, Ulm, Germany
12. Agaplesion Bethesda Clinic Ulm, Ulm, Germany
13. Hospital of Slagelse. Region Sjaelland, Slagelse, Denmark
14. Charles University, Czech Republic
15. Physical Medicine and Rehabilitation Department, Parc de Salut, Barcelona, Spain
17. Nova Medical School, Lisbon, Portugal
18. Centro Hospitalar Lisboa Central, Hospital de Santa Marta, Portugal
19. Aging Research Center, Karolinska Institutet, Stockholm, Sweden
20. Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart, Rome, Italy
21. Department of Geriatrics, Ghent University Hospital, Ghent, Belgium

*DSR, SH, and KP contributed equally to this work.

**Corresponding author:** Dolores Sanchez-Rodriguez, MD PhD.

Geriatrics Department, Centro Fòrum – Hospital Del Mar, Parc Salut Mar
C/ Llull 410, 08019, Barcelona, Spain.
Tel: +34 93 248 8532 / +34 609 778 331
Email: dolores.sanchez@uliege.be

**Funding source:** This research did not receive any funding from agencies in the public, commercial, or not-for-profit sectors.

**Word count of the main document:** 598 words

**Summary:** Our study will determine the prevalence, incidence, risk factors, and clinical outcomes of acute sarcopenia according to the revised European consensus on definition and diagnosis (EWGSOP2).
Research letter

Sarcopenia in acute care patients: Protocol for the European Collaboration of Geriatric Surveys: Sarcopenia EAMA9+ project

To the Editor:

Sarcopenia is a disease characterized by a progressive loss of skeletal muscle mass and strength, and related to physical impairment, disability, worse clinical outcomes and mortality in all healthcare settings (1). Importantly it is also reversible, with tailored exercise and nutritional support (1)(2). Sarcopenia prevalence varies widely depending on the criteria, measurement methods, and cut-off points used for its assessment (1)(2); to date few studies addressed the issue of sarcopenia in hospitalized older patients, rendering it an under-recognized clinical entity (3)(4). In 2015 the European Geriatric Medicine Society (EuGMS) founded the Special Interest Group on Sarcopenia, which aims to bridge the gaps between clinical practice and research (“Action-Research Philosophy”) by promoting collaborations between international scientific societies and institutions, and launching, in 2018, the revised European consensus on the definition and diagnosis on sarcopenia (EWGSOP2) (1).

We aim to prospectively evaluate the prevalence and incidence of sarcopenia (as defined by the EWGSOP2 criteria) in hospitalized patients across Europe (Belgium, Denmark, Germany, Italy, the Czech Republic, Poland, Portugal, Spain, and the United Kingdom), to assess risk factors associated with its presence or incidence, and to assess sarcopenia-related adverse clinical outcomes.

Study participants are patients aged ≥70 years admitted to acute medical units. Exclusion criteria are anticipated length of hospital stay <24 hours, and inability to perform the hand-grip test. Each study partner will collect data for first 100 consecutive patients meeting the entry criteria. By including 900 participants we will be able to detect 10% incidence of
sarcopenia with an error of approximately 2% (the exact 95% confidence interval ranging from 8.04 to 11.96%).

**Primary outcomes** include: 1) Prevalence of sarcopenia on admission (±48h) and 2) Incidence of sarcopenia between admission (±48h) and discharge (±24h). **Secondary outcomes** are: 1) Risk factors for the development of sarcopenia 2) In-hospital sarcopenia associated adverse outcomes (incidence of hospital-acquired infections, falls, delirium, length-of-stay, and mortality), and 3) Post-discharge adverse outcomes (institutionalization, hospital readmissions, falls, disability, and mortality) at 3- and 12-month follow-up.

The new EWGSOP2 sarcopenia diagnostic criteria will be followed (1)(6)(7). These include, assessment of muscle strength with isometric hand-grip test (cut-off points <27kg, men; <16kg, women) (1); gait speed (4-m walk, <0.8m/s) (1), and calf-circumference (<31cm) (1). The SARC-F questionnaire (8) will be used on admission, 3- and 12-month telephone follow-up. We will assess malnutrition (Global Leadership Initiative on Malnutrition (GLIM) criteria) (9)(10), physical frailty (FRAIL scale, Fried phenotype), functional status (Barthel’s, basic (ADL), and instrumental (IADL) activities of daily living), and cognition (Mini-Mental State Examination, Confusion Assessment Method, Geriatric Depression Scale).

The study was registered in ClinicalTrials.gov (2018/8355/I) and is being approved by local ethics committees. Data will be treated in accordance with the General Data Protection Regulation of the European Parliament and Council (GDPR 2016/679).

**Conclusions and implications:** The overall goal is to establish an epidemiological base for future geriatric research in Europe, in the previously largely overlooked area of sarcopenia in older hospitalized patients. Sarcopenia increases with age, especially after the age of 80 years, due to accumulation of both age-dependent and independent risk factors. Inflammaging, inactivity, and malnutrition may play particularly significant roles (1). Sarcopenia can be
prevented, and when developed can be a target for therapeutic actions. However, at present, there is limited knowledge of its prevalence and incidence in a real-world hospital population. The new EWGSOP2 guidelines offer a pragmatic approach which is more applicable to patients in an acute medical setting, and we intend to establish prevalence and incidence data, as well as important insights into risk factors for sarcopenia. We foresee that our results will have crucial implications for future research, clinical practice, and policies for optimal aging.

**Funding source:** This research is not receiving any commercial sponsorship.

**Conflicts of interests:** All authors declare no conflicts of interest.

**REFERENCES**


Recruitment
• Soon after hospital admission
  • Consent to participate and access notes for completion of demographics, blood test results & complications

Admission assessment
• Within 48 hours of admission
  • Questionnaires to include Barthel, SARC-F, mini-mental state examination...
  • Hand grip strength, gait speed (4 metres) and postural blood pressure if able, calf circumference

Discharge assessment
• Within 24 hours of discharge
  • Repeat Barthel, hand grip strength, gait speed (4 metres), calf circumference
  • Incidence of complications (falls, infections...)

3 month follow-up
• 3 months post-discharge - telephone follow-up
  • Repeat SARC-F & Barthel questionnaires
  • Information on complications (hospital readmission, institutionalization…)

12 month follow-up
• 12 months post-discharge - telephone follow-up
  • Repeat SARC-F & Barthel questionnaires
  • Information on complications (hospital readmission, institutionalization…)

Figure
Supplementary Material
Click here to download Supplementary Material: Methods appendix_European Collaboration EAMA Sarcopenia 9+ _jg_svh.docx